FDA BIMO Inspection Prep: An Oversight Stress-Test, Not a Binder Checklist

At a glance

• An FDA Bioresearch Monitoring (BIMO) inspection under Compliance Program 7348.811 is not a tidiness audit. The program directs investigators to verify subject safety and the accuracy and reliability of the data your study submitted to FDA.
• The inspector’s central move is a trace: comparing the data submitted to FDA against source documents and case report forms (CRFs), then following discrepancies back to their cause. Neat binders do not survive a broken trace.
• Two tracks dominate prep. A data-integrity track (source-to-submission reconstruction) and a delegation/oversight track (who was authorized to do what, and whether the investigator actually supervised).
• Your delegation log, your protocol-deviation handling, and your consent documentation are read as evidence of oversight as practiced, not oversight as described in an SOP.
• Outcomes are classified NAI, VAI, or OAI. A Form FDA 483 lists observed deviations; the classification, set later by the FDA center, determines what follows.
• Map readiness to inspection tracks, not to document types. A binder organized by artifact hides exactly the cross-record connections the inspector is paid to test.

A BIMO inspection feels procedural from the outside: a preannounced visit, a request for records, a Form 483 at the close. Treating it that way is the most common and most expensive mistake. The inspector is not grading your filing system. They are testing whether the oversight you claim on paper actually happened, by following your data and your decisions to their source. This guide maps preparation to what FDA Compliance Program 7348.811 actually directs the inspector to do, so your readiness reflects the inspection as practiced rather than a generic Investigator Site File (ISF) checklist.

What a BIMO inspection is really testing

FDA established the BIMO program to protect the rights, safety, and welfare of human subjects and to verify the accuracy and reliability of clinical study data submitted to FDA in support of research or marketing applications. Compliance Program 7348.811 states this as the program’s objective directly: inspections exist to protect subjects, to verify data reliability, and to assess compliance with FDA’s regulations governing study conduct. Read that order carefully. Subject safety and data reliability come first; “compliance” is assessed in service of those two ends, not as paperwork for its own sake.

That framing changes what prep should optimize for. A binder that is complete but cannot be reconciled to source is worse than useless: it documents a problem. The inspector is looking for whether your oversight is real, and the corpus that governs them tells them exactly how to find out.

The timing of an inspection also shapes its character. Per 7348.811, when an inspection results from FDA’s receipt of a marketing application or submission, it includes a comparison of the data submitted to FDA against source documents and CRFs. For surveillance or for-cause inspections of ongoing studies, the program notes that data comparison may be limited to source documents and CRFs because submitted data may not yet exist. Knowing which kind you face tells you how far back the trace will reach.

How 7348.811 drives the inspector: the data-audit track

The defining activity of a clinical-investigator BIMO inspection is data verification. Compliance Program 7348.811 directs the inspector to compare source records against data line listings for completeness and accuracy, and where discrepancies appear between source documents and line listings, to compare the source documents with CRFs to locate the source of the error. The inspector is explicitly told to escalate immediately to their supervisor when discrepancies between CRFs and data line listings appear, because that pattern may suggest systemic data-management issues.

This is the source-to-submission trace, and it is the heart of the data-integrity track. The inspector picks data points, often primary or key endpoint and safety data, and walks them backward: submission to line listing to CRF to the original source record. 7348.811 directs the inspector to evaluate source records against the expectation that they are attributable, legible, contemporaneous, original, accurate, and complete, and to confirm that source records document subject eligibility, required study visits and procedures, and safety monitoring including adverse-event documentation.

ICH E6(R3) §9.5 reinforces the records side of this: essential records must be available to regulatory authorities, monitors, auditors, and IRBs/IECs upon request to enable evaluation of trial conduct and to ensure the reliability of trial results. Availability here means reconstructable, not merely present. The sponsor’s own monitoring is meant to have already done a version of this trace; ICH E6(R3) §3.11.4.5.4 directs monitoring to check the accuracy, completeness, and consistency of reported trial data against source records and to verify that higher-criticality data are consistent with the source. If your monitoring found nothing because it never looked source-to-submission, the inspector will be the first to run that test.

The delegation and oversight track

The second track is where confident teams most often stumble. On day one, expect a request for the delegation log, and expect it to be cross-checked against who actually performed and signed for tasks. ICH E6(R3) §2.3.1 is unambiguous: an investigator may delegate trial-related activities, but retains ultimate responsibility and must maintain appropriate oversight to ensure participant rights, safety, and well-being and the reliability of data, with the level of oversight proportionate to the importance of the data and the risk to participants. Delegation does not transfer accountability. It creates an obligation to supervise.

E6(R3) §2.3.1 also requires that the level of oversight be proportionate, and the guideline requires that a record be maintained of the persons and parties to whom activities were delegated. The federal regulation makes the same point in its own register: under 21 CFR 312.60, an investigator is responsible for ensuring the investigation is conducted according to the signed investigator statement, the investigational plan, and applicable regulations, and for protecting the rights, safety, and welfare of subjects. That signed statement is the Form FDA 1572, which 21 CFR 312.53 requires the sponsor to obtain before an investigator begins, and in which the investigator personally commits to conduct or supervise the investigation and to ensure associates and employees are informed of their obligations.

7348.811 closes the loop on the inspection side: the program directs the inspector to compare the Form FDA 1572 (or the investigator agreement for device and animal studies) against the assignment background materials, and to determine when the investigator assumed responsibility and whether the responsible investigator changed during the study. The delegation track, in other words, is the 1572 made auditable. The inspector asks whether the people who touched the data were authorized and trained, and whether the investigator’s supervision left a trace.

Investigator-site versus sponsor or CRO inspections

The same program covers both clinical investigators and sponsor-investigators, but the questions differ. A site inspection under 7348.811 centers on source records, consent, delegation, investigational-product control, and the investigator’s own reports. A sponsor-investigator, who both initiates and conducts a study, must comply with the requirements applicable to both sponsors and investigators, and 7348.811 points to Compliance Program 7348.810 for the sponsor-side responsibilities.

The practical distinction: at a site, the inspector traces individual subjects’ data to source and tests whether the investigator supervised delegated staff. At a sponsor or CRO, the focus shifts upstream to oversight systems, monitoring, and whether issues found at sites were escalated and corrected. ICH E6(R3) §3.9.3 anchors the sponsor’s role here: the sponsor must determine trial-specific criteria for classifying protocol deviations as important, where important deviations are those that may significantly affect data completeness, accuracy, or reliability, or participant rights, safety, or well-being. A sponsor that cannot show how it defined “important,” detected it, and acted on it has an oversight gap, regardless of how clean any single site looks.

The records they pull and the trace they run

The table below maps 7348.811 inspection focus areas to the records the inspector traces and the in-corpus regulatory basis for the underlying obligation.

7348.811 inspection focus	Records/evidence traced	Regulatory basis (in-corpus)
Data verification (source-to-submission)	Source records vs. data line listings vs. CRFs; discrepancy reconciliation	7348.811 (Source Records; Inspection Procedures); ICH E6(R3) §3.11.4.5.4 (monitoring vs. source)
Authority and delegation	Form FDA 1572 vs. assignment; delegation log; date investigator assumed responsibility	7348.811 (Authority and Administration); 21 CFR 312.53; 21 CFR 312.60; ICH E6(R3) §2.3.1
Informed consent	Signed/dated consent forms; consent process documentation; consent before participation	ICH E6(R3) §2.8.7; 21 CFR 312.64(b) (case history documents consent obtained prior to participation)
Protocol deviations	Deviation log; review and corrective action; communication to IRB and sponsor	ICH E6(R3) §2.5.3, §3.9.3; 7348.811 (deviation review)
Safety reporting	Adverse-event records; serious-AE reports to sponsor; causality assessment	21 CFR 312.64(b); ICH E6(R3) §3.11.4.5.4
Records access	Permitting FDA access to, and copying of, records and reports	21 CFR 312.68 (investigator); 21 CFR 312.58 (sponsor); ICH E6(R3) §9.5

A note on consent and financial disclosure. The brief flags that 21 CFR Part 50 (informed consent) and 21 CFR Part 54 (financial disclosure) are not yet in this corpus. The closest in-corpus basis is ICH E6(R3) §2.8.7, which requires the consent form to be signed and dated by the participant (or legally acceptable representative) prior to trial participation, and 21 CFR 312.64(b), which requires the investigator’s case history to document that informed consent was obtained prior to participation. For financial disclosure, 21 CFR 312.64(d) requires the investigator to provide the sponsor with sufficient accurate financial information; treat the Part 50/Part 54 specifics as a documentation gap to confirm against the regulations directly, not as a settled in-corpus claim.

Using the public BIMO inspection-metrics database

FDA publishes BIMO inspection metrics, and most teams never open them. This is intelligence, not compliance evidence, so no regulatory citation attaches to using it: the database does not change your obligations. What it offers is calibration. Looking at the distribution of classifications and the frequency of observation types across clinical-investigator inspections tells you where scrutiny concentrates and where the common 483 observations cluster. Treat it as a benchmarking tool: if a category shows up repeatedly across the field, assume your inspector knows to look there, and rehearse that trace before they arrive.

What the June 2024 draft guidance changes for your readiness

FDA issued draft guidance in June 2024 on its BIMO inspection processes. As draft guidance it is non-binding and is not part of this regulatory corpus, so nothing below is cited as a current regulatory requirement. The directional signal for readiness is consistency: the controlling obligations remain those in 7348.811, ICH E6(R3), and 21 CFR Part 312. Read the draft when you finalize prep, but anchor your readiness to the binding program and regulations above, and do not let a non-final guidance reshape commitments that the regulations already fix. If the final guidance lands before your inspection, reconcile it against this corpus and surface any tension to QA rather than smoothing it over.

Outcomes: NAI, VAI, OAI, and the Form 483

A BIMO inspection ends with a classification, and the stakes live there. Per 7348.811, the three classifications are No Action Indicated (NAI), where no objectionable conditions were found or any found do not justify regulatory action; Voluntary Action Indicated (VAI), where objectionable conditions were found but do not meet the threshold for regulatory action; and Official Action Indicated (OAI), where objectionable conditions were found and regulatory action should be recommended.

Classification	What it means (per 7348.811)	Practical consequence
NAI	No objectionable conditions, or none significant enough to act on	Close-out; no further action expected
VAI	Objectionable conditions found, below the regulatory-action threshold	Voluntary correction; respond to any 483 and remediate
OAI	Objectionable conditions found warranting recommended action	Escalation; possible advisory/enforcement follow-up

The Form FDA 483 is separate from the classification. Per 7348.811, the inspector issues a Form FDA 483 at the conclusion of the inspection when deviations from applicable regulations are observed, and any observation that does not constitute a regulatory deviation is not listed on it. The 483 documents what the inspector saw; the classification, determined later by the FDA center, decides what it means. The program also notes that the inspector informs the investigator they may submit a written response to the 483. Respond promptly, factually, and with concrete corrective and preventive actions; a strong response addresses root cause, not just the listed instance.

A readiness checklist mapped to inspection tracks

Organize prep by track, not by binder. Each item below ties to what the inspector actually traces.

Data-integrity track

• Rehearse a source-to-submission trace yourself: pick primary endpoint and safety data points and walk them from submission/line listing to CRF to source. 7348.811 runs exactly this.
• Confirm source records are attributable, legible, contemporaneous, original, accurate, and complete, the quality attributes 7348.811 directs the inspector to assess.
• Reconcile CRFs to source before the visit; a CRF-to-line-listing discrepancy is the trigger 7348.811 tells inspectors to escalate as a possible systemic issue.

Delegation and oversight track

• Have the delegation log current and consistent with who actually signed for tasks. ICH E6(R3) §2.3.1 makes the investigator’s proportionate oversight the obligation, not the delegation itself.
• Confirm the Form FDA 1572 matches the assignment and that any change in the responsible investigator is documented and dated, per 7348.811 and 21 CFR 312.53.
• Be ready to show training records demonstrating delegated staff were qualified for their assigned activities (ICH E6(R3) §2.3.1).

Consent and safety-reporting track

• Verify each consent form is signed and dated prior to participation, with the consent process documented, per ICH E6(R3) §2.8.7 and 21 CFR 312.64(b).
• Confirm serious adverse events were reported to the sponsor with a causality assessment, as 21 CFR 312.64(b) requires.
• Have protocol deviations logged, reviewed, and (for important ones) explained with preventive measures, per ICH E6(R3) §2.5.3, and confirm the sponsor’s “important deviation” criteria were applied, per §3.9.3.

Where teams get it wrong

The recurring failure is preparing the artifact instead of the trace. Teams assemble a flawless ISF, then cannot connect a single submitted data point to its source under questioning. A second failure is treating delegation as a formality: staff perform tasks they were never delegated, or the investigator signs a 1572 commitment to supervise that the records do not show being honored. ICH E6(R3) §2.3.1 and 21 CFR 312.60 both put accountability on the investigator regardless of how work was distributed. A third is conflating the 483 with the verdict; the classification (NAI/VAI/OAI) is decided afterward by the center, so a 483 with observations is not automatically an OAI, and a clean close is not guaranteed by a tidy binder.

One alignment worth stating plainly, since the in-scope regulations agree here rather than conflict: ICH E6(R3) §9.5 and 21 CFR 312.68 and 312.58 both require records to be available to FDA for access, copying, and verification on request. The ICH guideline and the federal regulation point the same direction on records availability, so there is no tension to flag on that point.

Software and well-designed processes can make this oversight easier to evidence, but no tool makes you compliant. Under 21 CFR 312.60, the investigator remains responsible for the conduct of the study, and under ICH E6(R3) §2.3.1, that responsibility survives every delegation. Prepare for the trace, document the oversight, and let the binder be a byproduct of work that actually happened.

Sources

• FDA Compliance Program 7348.811, Bioresearch Monitoring: Clinical Investigators and Sponsor-Investigators (version 2020) — https://www.fda.gov/media/75927/download
• ICH E6(R3) Good Clinical Practice (version r3, adopted 06 January 2025) — https://www.ich.org/page/efficacy-guidelines
• 21 CFR Part 312, Investigational New Drug Application (version 2026-04, content current as of 4/14/2026)